Acute effects of amphetamine and related psychostimulants on impulsivity: a systematic review of clinical trials was written by Arkell, Thomas R.;Bradshaw, Kristina;Downey, Luke A.;Hayley, Amie C.. And the article was included in Addiction Biology in 2022.Application of 83799-24-0 The following contents are mentioned in the article:
Evidence for acute amphetamine effects on behavioral impulsivity in healthy populations remains elusive and, at times, mixed. This review collates and reviews the clin. literature on the acute effects of amphetamines on measures of behavioral impulsivity in healthy adults. Randomised and placebo-controlled clin. trials that assessed behavioral impulsivity following the administration of an acute dose of amphetamine or a related psychostimulant (including amphetamine analogs and methylphenidate) were eligible for inclusion. The EBSCOHost, SCOPUS, PsychNet, Web of Science and ProQuest databases were searched from inception to 26 Apr. 2021. Study selection, data extraction and the Cochrane risk of bias assessments were conducted by two independent reviewers. Reporting follows PRISMA guidelines, and the review was registered a priori on the PROSPERO database (Registration No: CRD42021249861). A total of 20 studies were included, comprising a total of 737 participants. Overall, results indicate that low-moderate doses of amphetamine and related psychostimulants may improve (i.e., reduce) impulsive responding without compromising performance, reflecting enhanced inhibitory control of behavior. These effects are mild and appear most pronounced in individuals with high baseline impulsivity. This review highlights the need for greater consistency in behavioral task selection and future high-quality and well-designed studies to address current concerns around growing prescription psychostimulant use and misuse. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application of 83799-24-0).
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Application of 83799-24-0
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem